Polifarma wins the German M&A Award 2025 for “Best Family Business Deal”

Polifarma S.p.A. has been awarded the German M&A Award 2025 in the Best Family Business Deal category for the acquisition of the German company Hennig Arzneimittel, a recognition that celebrates the strategic vision and financial solidity behind an operation that unites family heritage with international growth.

The M&A Award, presented annually in Berlin by the Bundesverband Mergers & Acquisitions (BMA) honors outstanding M&A transactions distinguished by innovation, integration capability, value creation, and positive impact on the economy.

During the gala evening, Federal Minister Dorothee Bär (Ministry of Research, Technology and Space) stated that “the future is created when talents, ideas and technologies come together,” underlining the role of mergers and acquisitions as a driver of innovation and competitiveness.

In its motivation, the jury highlighted that “the core of this operation was represented by employees, people, and values. Throughout the integration process, the focus consistently remained on collaboration and the human dimension. This is the real success story behind this deal.”

A recognition of both industrial and human value

The acquisition of Hennig Arzneimittel, completed in February 2025, marked a decisive step in the international growth of the pharmaceutical group, which now includes Polifarma S.p.A., Polifarma Benessere, and Hennig Arzneimittel GmbH & Co. KG.

Based near Frankfurt and with over 125 years of history, Hennig Arzneimittel is a leading German pharmaceutical company specializing in neurology, psychiatry, gastroenterology, and cardiology, as well as operating as a CDMO (Contract Development and Manufacturing Organization).
The company employs about 300 people, exports to more than 27 countries, and operates a state-of-the-art facility producing over 6 billion units annually.

With more than a century of experience, Polifarma, part of the Final Group led by Luisa Angelini, operates in Cardiology, Gastroenterology, Central Nervous System and Ophthalmology, and is strongly committed to innovation, including the development of Digital Therapeutics (DTx).
The acquisition of Hennig consolidates a long-standing collaboration that began in 2008 and transforms it into a shared industrial and cultural project, founded on common values and a people-centered approach.

The German M&A Award 2025 thus recognizes not only the strategic excellence of the transaction but also the way it was carried out, with responsibility, collaboration, and a strong human focus, values that have always defined Polifarma’s identity.